Singapore 9 March, 2016: BCAL Diagnostics has been selected as one of five winning startups from the India, Southeast Asia and Oceania Region that will proceed to the global finals of the 1776 Challenge Cup in Washington DC.
The 1776 tournament brings together world-changing startups in the running to win investment as well as harnessing international connections.
BCAL Diagnostics, based in Sydney, Australia, is determined to transform the lives of women globally by creating an easily accessible blood test for the detection of breast cancer.
“BCAL is at the forefront of a diagnostic tool that is revolutionary. This technology will impact the lives of millions of women around the world,” said Jayne Shaw, Chairman of BCAL Diagnostics.
Breast cancer is the most common cancer amongst women, but the current gold standard for detection – mammography – only has an accuracy of 40-70%, and is limited by various factors. Initial trials of the BCAL blood test have demonstrated an accuracy of over 90%
At the 1776 Challenge Cup global finals in June, 45 winners from nine regions will compete for over US$1 million in cash and equity prizes, and mix with investors, customers and media from around the world.
1776 is a global incubator and seed fund helping startups transform industries that impact millions of lives every day—education, energy & sustainability, health, transportation and cities.
BCAL Diagnostics was represented at the regional competition in Singapore by Dr Peter French, Director and Scientific Advisor, and Jayne Shaw, Chairman. Dr French will represent the company at the global finals.